Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non‐critical COVID ‐19 pneumonia: A double‐blind randomized, placebo‐controlled clinical trial
Faranak Sedighi, Mehran Zarghami, Fatemeh Alizadeh arimi, Mahmood Moosazadeh, Shahram Ala, Roya Ghasemian, Hossein Mehravaran, Forouzan Elyasi
Neuropsychopharmacology Reports, doi:10.1002/npr2.12327
Introduction: Selective serotonin reuptake inhibitors are considered the drugs, whose effectiveness in viral pandemics has been studied. The aim of this study was to evaluate of adding fluoxetine to the treatment regimen of patients with COVID-19 pneumonia.
Methods: This study was a double-blind randomized placebo controlled clinical trial .36 patients in the fluoxetine and 36 patients in the placebo group were enrolled. Patients in the intervention group were first treated with fluoxetine 10 mg for 4 days and then the dose of 20 mg was continued for 4 weeks. Data analysis was conducted using SPSS V. 22.0. Results: There was no statistically significant difference between the two groups in terms of clinical symptoms at the beginning of the study and also the score of anxiety and depression, oxygen saturation at the time of hospitalization, mid-hospitalization and discharge periods. The need for mechanical ventilator support (p = 1.00), the need for admission in the intensive care unit (ICU) (p = 1.00), rate for mortality (p = 1.00), and discharge with relative recovery (p = 1.00) were not significantly different between the two groups. The distribution of CRP within the study groups showed a significant decrease during different time periods (p = 0.001), and although there was no and at discharge (p = 0.585), mid-hospital CRP showed a significant decrease in the fluoxetine group (p = 0.032).
Conclusion: Fluoxetine resulted in a faster reduction of patients' inflammation without association with depression and anxiety.
reported the side effects of fluoxetine and the evidence of reduced inflammatory processes was observed in the fluoxetine group. It is suggested that in future studies, the sample size would be calculated with the higher power to examine whether stronger findings can be achieved with larger sample size. Also the dose of the drug could be increased more rapidly and, if possible, increasing the dose to higher than 20 mg per day, can lead to greater efficacy of the drug.
| CON CLUS ION
ACK N OWLED G M ENTS The study was done with the financial support from the Vice Chancellor for Research of MAZUMS. We thank all those who helped us in this study. We also thank the patients for their cooperation in the fulfillment of this study and all hospital staff involved in patient treatment.
FU N D I N G I N FO R M ATI O N This study was supported by the Mazandaran University of Medical Sciences. (Grant number = 8354).
CO N FLI C T O F I NTER E S T S TATEM ENT The authors declare that they have no conflict of interest.
References
Ahmadi Livani, Gohardehi, Azizi, Hashemvarzi, Taghavi et al., Multisectoral actions of mental health during the COVID-19 pandemic in Mazandaran province of Iran, Neuropsychopharmacol Rep,
doi:10.1002/npr2.12239Azizi, Elyasi, Roodposhti, Bradycardia caused by interaction of venlafaxine and cyclosporine: a case report, Caspian J Intern Med
Baller, Hogan, Fusunyan, Ivkovic, Luccarelli et al., Neurocovid: pharmacological recommendations for delirium associated with COVID-19, Psychosomatics,
doi:10.1016/Fj.psym.2020.05.013Bishara, Kalafatis, Taylor, Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents, Ther Adv Psychopharmacol,
doi:10.1177/F2045125320935306Boland, Verduin, Ruiz, Antidepressants
Caiaffo, Oliveira, De Sá, Neto, Anti-inflammatory, antiapoptotic, and antioxidant activity of fluoxetine, Pharmacol Res Perspect,
doi:10.1002/prp1002.1231Carpinteiro, Edwards, Hoffmann, Kochs, Gripp et al., Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells, Cell Rep Med,
doi:10.1002/prp1002.1231Fda, Flouxetine, None
Gulbins, Palmada, Reichel, Lüth, Böhmer et al., Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs, Nat Med,
doi:10.1038/nm.3214Hiles, Baker, De Malmanche, Attia, Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis, Psychol Med,
doi:10.1017/s0033291712000128Hoertel, Rico, Vernet, Beeker, Jannot et al., Association between SSRI antidepressant use and reduced risk of intubation or death in hospitalized patients with coronavirus disease 2019: a multicenter retrospective observational study,
doi:10.1038/s41380-41021-01021-41384Kamali, Moosazadeh, Azizi, Ghasemian, Reskati et al., Anxiety due to COVID-19 among healthcare providers during pandemic: a web-based cross-sectional survey in Iran, Neuropsychopharmacol Rep,
doi:10.1002/npr2.12213Karimi-Khouzani, Heidarian, Amini, Anti-inflammatory and ameliorative effects of gallic acid on fluoxetine-induced oxidative stress and liver damage in rats, Pharmacol Rep,
doi:10.1016/j.pharep.2017.1003.1011Köhler, Freitas, Stubbs, Maes, Solmi et al., Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis, Mol Neurobiol,
doi:10.1001/jama.2020.22760Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2020.22760Montazeri, Vahdaninia, Ebrahimi, Jarvandi, The hospital anxiety and depression scale (HADS): translation and validation study of the Iranian version, Health Qual Life Outcomes,
doi:10.1186/1477-7525-1181-1114Németh, Szûcs, Vitrai, Juhász, Németh et al., Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: a retrospective case-control study, Ideggyogy Sz,
doi:10.18071/isz.18074.10389Oskotsky, Marić, Tang, Oskotsky, Wong et al., Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial, Neuropsychopharmacol Rep
Reis, Moreira-Silva, Silva, Thabane, Milagres et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health,
doi:10.1016/s2214-1109x(1021)00448-00444Schloer, Brunotte, Goretzko, Mecate-Zambrano, Korthals et al., Targeting the endolysosomal host-SARS-CoV-2 interface by the clinically licensed antidepressant fluoxetine, Biorxiv,
doi:10.1080/22221751.2020.1829082Williamson, Walker, Bhaskaran, Bacon, Bates et al., OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients, medRxiv,
doi:10.1038/s41586-020-2521-4Yang, Ding, Hu, Zhang, Sheng, Reliability and validity of a Chinese version of the HADS for screening depression and anxiety in psycho-cardiological outpatients, Compr Psychiatry,
doi:10.1016/j.comppsych.2013.1008.1012Zimniak, Kirschner, Hilpert, Geiger, Danov et al., The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2 in human lung tissue, Sci Rep,
doi:10.1038/s41598-021-85049-0
